Source: CureToday articles
Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.
Recent Content
- Optune Lua Receives CE Mark in Europe for Metastatic NSCLC
- Study: Mineral and Vitamin Levels in Pregnancy Linked to Midlife Blood Pressure
- How to Best Navigate a Diagnosis of Lung and Head and Neck Cancer
- Joy Anderson Reflects on Her Rare Blood Disorder Diagnosis Journey
- Study Links PAK5 to Poor Outcomes and Drug Resistance in HER2-Positive Breast Cancer
- The Burst of Spring: Reflection for Those Living with Cancer
- Introducing Obecabtagene Autoleucel: A New Chapter in ALL Treatment
- “We’ve Got to Get This Right From the Start”: Expert Discusses MDPNP Impacts on Pharmacies
- Full COVID-19 mRNA Vaccination Course Induces Long-Term Antibody, Memory B-Cell Response
- A Pharmacist’s Guide to Lung Cancer and Its Key Treatments